When testosterone isn't the answer
Sleep apnea, opioids, alcohol, severe energy deficit, thyroid disease, prolactinoma. The situations where treating the cause beats treating the hormone.
Don’t treat the number. Treat the man.
A low testosterone result is not a diagnosis. It is a finding that requires an explanation, and in a substantial proportion of men the explanation is something else — something that is also causing the symptoms, and something that testosterone will not fix.
This is not a fringe position. The Endocrine Society’s 2018 clinical practice guideline states that many men with secondary hypogonadism have potentially reversible causes “that may be managed without need for testosterone treatment.” The same guideline instructs clinicians not even to test men who are acutely ill or on short-term medications that suppress testosterone, and to include in any evaluation a general health assessment to exclude systemic illness, eating disorders, excessive exercise, sleep disorders, and recreational drug or medication effects.
Read that as what it is: the world’s largest endocrine society telling clinicians that a meaningful share of low testosterone results should lead somewhere other than a prescription.
This page is about those men. Some of what follows will complicate the standard story, including in places where we would have preferred a cleaner answer.
When the answer is weight loss
This is the largest single category, and the effect is real and quantified.
A meta-analysis by Corona and colleagues covering 24 studies found that weight loss through a low-calorie diet raised total testosterone by an average of 2.87 nmol/L (95% CI 1.68–4.07) — roughly 83 ng/dL. Weight loss after bariatric surgery raised it by 8.73 nmol/L (95% CI 6.51–10.95) — roughly 251 ng/dL, about three times the diet effect. The degree of weight lost was the strongest predictor of how much testosterone rose.
A 2025 validation study in Andrology looked specifically at hypogonadal men undergoing bariatric surgery: in 69 men, mean testosterone rose from 208 ng/dL to 371 ng/dL, and 45% reached eugonadal status (defined as at least 350 ng/dL) over a median follow-up of around 13 months.
Two things follow.
Weight loss is the most effective non-pharmacological intervention for testosterone that exists. A 250 ng/dL rise is not a marginal effect — it is comparable to what many men achieve on replacement therapy, achieved by treating the cause rather than overriding it.
It doesn’t work for everyone. Fifty-five percent of those men did not reach the eugonadal threshold despite substantial surgical weight loss. Some men have obesity and an independent cause of hypogonadism. Weight loss first does not mean weight loss only.
This is why the Endocrine Society’s July 2026 statement says that where obesity with a BMI above 27 is the only identified cause, weight loss is typically first-line therapy. Not the only therapy. First.
Evidence: 🟢 Established
See also: Obesity, GLP-1 Medications and Testosterone, where the newer pharmacological routes to the same endpoint are covered.
When the answer is treating sleep apnea — with an important complication
Here we have to correct something this site would rather be able to say simply.
Obstructive sleep apnea is strongly associated with low testosterone. It is also associated with fatigue, low libido, poor concentration, low mood and erectile dysfunction — the entire symptom cluster that sends men to get their testosterone checked. Diagnosing and treating OSA in a man with these symptoms is unambiguously good medicine.
But the evidence that treating it raises testosterone is not there.
A meta-analysis published in PLOS ONE pooling seven studies across nine cohorts and 232 men found that CPAP had no significant effect on testosterone. Total testosterone: standardized mean difference −0.14 (95% CI −0.63 to 0.34, p=0.558). Free testosterone: 0.16 (95% CI −0.09 to 0.40, p=0.211). Restricting the analysis to the randomized controlled trials against a control group, the result was −0.05 (95% CI −0.38 to 0.27, p=0.757) — still null. Duration of CPAP treatment made no difference. The authors’ conclusion was that CPAP “has no influence on testosterone levels in men with OSA.”
A great many websites, including some written by physicians, state that treating sleep apnea will raise your testosterone. The best available synthesis says it does not.
What this actually means:
Much of the association between OSA and low testosterone probably runs through obesity, which causes both. Treat the apnea without changing the weight and the testosterone doesn’t move. Lose the weight and both improve — but the weight loss is doing the work.
What it does not mean: that treating OSA is optional. Untreated sleep apnea causes hypertension, cardiovascular disease, daytime somnolence, cognitive impairment and road traffic accidents. It also produces most of the symptoms men attribute to low testosterone. A man with untreated OSA who is given testosterone may well feel somewhat better while an independent and dangerous condition goes unaddressed.
There is also a signal running in the other direction: testosterone therapy may worsen sleep apnea, plausibly in a dose- and formulation-dependent way. We were unable to verify the specific magnitude of that effect from primary sources and are not going to quote a figure — but it is a recognized concern and a reason to identify OSA before starting treatment rather than after.
So the honest framing is: treat sleep apnea because sleep apnea needs treating and because it may be causing your symptoms — not because it will fix your testosterone. On current evidence, it probably won’t.
Evidence: 🟢 Established that OSA needs treating · ⚫ Unsupported that CPAP raises testosterone
When the answer is changing a medication
Opioids
Opioid-induced androgen deficiency is common, dose-dependent, under-recognized, and frequently reversible.
Reported prevalence ranges from 19% to 86% depending on the diagnostic threshold used, with most studies above 50%. It varies sharply by route and drug: intrathecal morphine is associated with rates of 86 to 100%; high-dose methadone maintenance with around 75% in men.
The risk rises with dose, increasing notably above roughly 100 mg oral morphine equivalents per day. Long-acting preparations carry higher risk than short-acting at equivalent doses. Among individual agents, fentanyl, methadone and oxycodone carry the highest risk. Two are notably different: tapentadol appears to have minimal effect, attributed to its far lower μ-opioid receptor affinity, and buprenorphine has only limited endocrine effects and can be used for extended periods without inducing hypogonadism — which matters a great deal for men on medication-assisted treatment.
Reversibility: testosterone can normalize within about a month of opioid withdrawal in studies of heroin-dependent men. Whether the same holds for a chronic pain patient tapering a long-term prescription has not been established. That is a genuine evidence gap.
The clinical point stands regardless. A man on 200 mg morphine equivalents daily with a testosterone of 180 ng/dL does not have primary hypogonadism. He has a drug effect. Adding testosterone to the regimen treats the number and leaves the cause running.
Evidence: 🟢 Established that opioids suppress testosterone · 🟡 Promising on reversibility with dose reduction
Glucocorticoids
Glucocorticoids suppress the hypothalamic-pituitary-gonadal axis. In a case-control study of 152 men, active glucocorticoid use significantly reduced total and free testosterone, with a cumulative dose of 240 mg prednisone-equivalent or more producing detectable biochemical hypogonadism. Dexamethasone was disproportionately potent — a cumulative dose of only 18.9 mg was associated with a 7.5-fold increased risk of hypogonadism relative to other steroids. Men who had discontinued showed testosterone normalization, though with persistently elevated estradiol, suggesting recovery may be incomplete.
This is one moderate-quality study rather than a settled dose-response relationship, and should be read that way. The direction is not in doubt.
Evidence: 🟡 Promising
Everything else
A number of common medications lower testosterone by identifiable mechanisms:
- Antipsychotics — dopamine receptor blockade raises prolactin, which suppresses GnRH. Risperidone and haloperidol are notable offenders.
- Anticonvulsants — hepatic enzyme induction raises SHBG, lowering free testosterone even when total looks acceptable. Phenytoin and carbamazepine in particular.
- 5-alpha-reductase inhibitors — finasteride and dutasteride block conversion of testosterone to DHT. Testosterone itself may rise; the androgenic effect in DHT-dependent tissues falls.
- Spironolactone — androgen receptor antagonism plus reduced testicular synthesis.
- Ketoconazole — potent inhibition of steroidogenesis; historically used deliberately for that purpose.
- Cytotoxic chemotherapy — direct Leydig cell and germinal epithelium damage, with alkylating agents carrying the highest risk.
- GnRH agonists and antagonists — profound suppression by design, as used in prostate cancer.
A medication review is not an optional preliminary. It is frequently the diagnosis.
When the answer is treating hyperprolactinemia
Prolactin suppresses GnRH, which suppresses LH and FSH, which lowers testosterone. It is one of the most satisfying findable causes in endocrinology, because treating it often restores testosterone without any replacement at all.
Dopamine agonist treatment — cabergoline or bromocriptine — reverses hypogonadotropic hypogonadism in roughly 50 to 65% of cases, with higher baseline testosterone and smaller tumour size predicting recovery.
Two assay traps are worth knowing about, because both cause men to be misdiagnosed.
Macroprolactinemia. Prolactin can circulate as large, biologically inactive aggregates — “big-big prolactin.” These are detected by the assay but do nothing physiologically. Macroprolactin is present in roughly 20% of samples with an elevated prolactin. It is usually asymptomatic and requires no treatment. It is identified by polyethylene glycol precipitation, and confirmed by gel-filtration chromatography. A man treated for hyperprolactinemia he does not functionally have is being treated for a laboratory artifact.
The hook effect. The opposite error, and more dangerous. In men with very large prolactinomas producing genuinely enormous prolactin concentrations — above 1,000 ng/mL — the sheer quantity of antigen saturates both antibodies in a two-site immunoassay and the signal collapses. The reported result comes back in the 30 to 120 ng/mL range: mildly elevated, easily dismissed. A macroadenoma gets misclassified as a non-functioning pituitary tumour. The fix is simple — dilute the serum and re-run — but only if someone thinks to ask.
Evidence: 🟢 Established
When the pituitary needs evaluating
Low testosterone with low or inappropriately normal LH and FSH points upstream. That combination warrants thinking about the pituitary, particularly alongside headaches, visual field changes, other pituitary hormone abnormalities, or a very low testosterone.
This is where measuring LH and FSH stops being a formality and becomes the whole point. A man with low testosterone and high LH has a testicular problem. A man with low testosterone and low LH has a problem above the testis, and it needs a name before it gets a prescription.
When the answer is thyroid treatment
Thyroid disease affects testosterone by two routes, and both distort the picture.
Hyperthyroidism raises SHBG, which raises total testosterone — sometimes into a comfortable-looking range while free testosterone is unremarkable or low. Hypothyroidism lowers SHBG, which lowers total testosterone while free testosterone is often preserved. Both are mechanistically reversible when the thyroid disorder is treated.
Hypothyroidism also produces fatigue, weight gain, low mood, cognitive slowing and reduced libido — a symptom profile essentially indistinguishable from the one attributed to low testosterone.
We could not verify specific magnitudes for these effects from primary sources, so we are not quoting numbers. The mechanism and the direction are well established. A TSH is a cheap test and it belongs in the workup.
Evidence: 🟡 Promising on magnitude · 🟢 Established on mechanism
When the answer is treating depression
This section requires more care than any other on this page, because the popular claim and the evidence pull in different directions and the stakes of getting it wrong are high.
Low testosterone and depression are associated. Prospective cohort data suggest low baseline testosterone predicts subsequent depression in older men. Depression also suppresses the HPG axis, so causation plausibly runs both ways.
Does testosterone treat depression? A meta-analysis by Walther and colleagues published in JAMA Psychiatry in 2019 pooled 27 randomized controlled trials and 1,890 patients and found a moderate positive effect of testosterone on depressive symptoms compared with placebo.
That sounds like a clear answer. Look at what sits underneath it.
The trials covered heterogeneous populations with diverse medical conditions and mood disorders — not a population of men with diagnosed major depressive disorder. And critically: baseline testosterone status was not a significant moderator of the effect. Neither was age.
That last finding deserves attention, because it undermines the story most people are telling. If testosterone relieved depression by correcting a deficiency, men who were actually deficient should respond better than men who weren’t. They didn’t. Whatever is producing the effect, it does not appear to be the correction of a hormonal deficit.
Current guidance advises against using testosterone as a sole treatment for major depressive disorder. It may be reasonable as one component of a broader approach in a man who is genuinely hypogonadal and depressed.
The clinical risk is specific and serious. A man with untreated major depression who is told his problem is hormonal, started on testosterone, and monitored for six months to see whether he feels better, is a man who has had effective treatment delayed by six months. Depression is dangerous. It has treatments that work. Testosterone is not reliably one of them.
Evidence: 🟠 Limited — a real but modest effect in heterogeneous populations, not moderated by testosterone status, and not a substitute for depression treatment
When the answer is managing chronic disease
Chronic kidney disease, cirrhosis, HIV, COPD, heart failure and active malignancy are all associated with low testosterone. The axis is suppressed by systemic illness, inflammation, malnutrition and the medications used to treat these conditions.
We looked for reliable prevalence figures for each and could not verify them to a standard we are willing to publish. The clinical principle does not depend on the numbers: in a man with significant systemic disease, a low testosterone is more likely to be a marker of illness severity than an independent problem, and the priority is the underlying condition.
The Endocrine Society’s guidance is direct on the acute version of this: don’t test men who are acutely ill or recovering from acute illness. The result will be low and it will not mean what it appears to mean.
When the answer is sleep
Not sleep apnea — sleep.
In a study of ten healthy young men, one week of five hours’ sleep per night reduced daytime testosterone by 10 to 15%. The authors compared the magnitude to ten to fifteen years of normal age-related decline.
Ten men is a small study, and they were young. But chronic sleep restriction is extraordinarily common, it independently produces fatigue, low mood, poor concentration and reduced libido, and it is not usually asked about before a testosterone level is ordered.
A man sleeping five hours a night has a plausible explanation for both his symptoms and his testosterone.
Evidence: 🟡 Promising
When the answer is eating more
Severe energy deficit suppresses the reproductive axis in men, as it does in women. Male athletes and soldiers under sustained energy restriction show suppressed testosterone, with one report of castrate-level testosterone following prolonged military training.
We should be careful here. A 2024 review in Endocrine Reviews notes explicitly that there are conflicting results across studies of hypogonadism in male athletes, and that the male-specific literature is limited compared with the equivalent research in women. We also could not find a reliable timeline for recovery of testosterone in men once energy intake is restored — a genuine gap.
What can be said: aggressive dieting, high training volume, and low energy availability plausibly suppress testosterone, and a man who is under-eating and over-training has a candidate explanation for a low result that is not addressed by a prescription.
Evidence: 🟠 Limited
When the answer is training less
Related, and frequently the same man. Very high training volume with inadequate recovery and inadequate energy intake suppresses the axis. The man who responds to fatigue and declining performance by training harder and eating less is applying the exact intervention that will make the underlying problem worse.
This is a difficult conversation, because the population most likely to seek testosterone testing overlaps heavily with the population most invested in training hard. It is also one of the more reversible causes on this page.
Evidence: 🟠 Limited
When the answer is fertility-directed treatment
If a man has low testosterone with low LH and FSH and wants children, replacement testosterone is the wrong drug. It will suppress what remains of his sperm production. The right approach stimulates the axis rather than overriding it.
This is covered fully in TRT and Fertility. It appears here because it belongs on any list of situations where the obvious treatment is the wrong one.
When the answer is alcohol
Chronic heavy alcohol use suppresses the gonadal axis through direct testicular toxicity, hepatic effects on SHBG and hormone metabolism, and central suppression.
We were unable to access the primary dose-response literature during this review and will not invent a threshold. One counterintuitive finding worth knowing about: acute low-dose alcohol has been reported to transiently increase testosterone in men, which is a reminder that the acute and chronic pictures differ and that single-timepoint observations mislead.
Evidence: 🟡 Promising on chronic heavy use · 🟠 Limited on dose-response
What happens if you treat with testosterone anyway
Suppose the reversible cause goes unaddressed and testosterone is prescribed regardless. Three things follow.
The cause continues. The prolactinoma keeps growing. The apnea keeps damaging the cardiovascular system. The depression goes untreated. Testosterone does not slow any of these.
The diagnosis becomes harder to make. Exogenous testosterone suppresses LH and FSH, which erases exactly the information needed to work out where the problem was. After six months on treatment, a man’s gonadotropins tell you about his prescription, not his pituitary. To evaluate him properly you now have to stop the testosterone and wait months for the axis to recover.
A reversible situation becomes a permanent one. The axis is suppressed. The testes shrink. Fertility falls. A man whose testosterone would have normalized with 15 kg of weight loss or an opioid taper is now on lifelong replacement for a condition he did not have.
We could not find an outcomes study quantifying these harms, and we are not going to present clinical reasoning as though it were a cited statistic. But the reasoning is sound, and it is the reason the Endocrine Society’s guideline sequences the evaluation the way it does.
The sequence
- Symptoms that plausibly relate to testosterone — not fatigue alone, which relates to almost everything.
- Correct measurement — two early-morning fasting samples, standardized assay. See How Testosterone Should Actually Be Tested.
- LH and FSH — this locates the problem. Skipping it means you don’t have a diagnosis.
- A cause — testicular, central, or systemic. See Why Is Testosterone Low?.
- Reversible contributors identified and addressed — medications, weight, sleep, alcohol, energy intake, thyroid, prolactin, chronic disease.
- Fertility intentions established — before the first dose. See TRT and Fertility.
- Then, if a genuine deficiency remains and the symptoms are ones testosterone plausibly improves — treatment, with monitoring.
Men who genuinely need testosterone exist, and they are frequently under-treated. This page is not an argument against replacement therapy. It is an argument for arriving at it through a diagnosis rather than instead of one.
What remains uncertain
How many men with low testosterone have a fully reversible cause. Nobody has quantified this in an unselected population. Clinical experience suggests it is a large fraction. That is an impression, not a statistic.
Whether opioid-induced hypogonadism reverses in chronic pain patients tapering long-term therapy. The one-month normalization data come from heroin-dependent men. The chronic pain population has not been studied.
Why CPAP doesn’t raise testosterone. The null result is reasonably solid. The mechanism — how much is confounding by obesity, how much is something else — is not established.
Whether treating depression raises testosterone. We could not establish this from available evidence in either direction.
How much weight loss is enough. The dose-response is broadly established, but there is no verified threshold at which a given man’s testosterone will normalize, and 55% of men in the bariatric study did not reach eugonadal status despite major weight loss.
Recovery timelines for energy-deficit-related suppression in men. Not characterized.
The harms of treating over an unaddressed reversible cause. Mechanistically clear, not quantified by any outcomes study we could find.
Questions patients ask
If my testosterone is low, I need testosterone.
Not necessarily. A low result requires an explanation, and often the explanation has its own treatment.
What the evidence showsThe Endocrine Society's 2018 guideline states that many men with secondary hypogonadism have potentially reversible causes that may be managed without testosterone treatment, and directs clinicians to evaluate for systemic illness, eating disorders, excessive exercise, sleep disorders, and medication effects.
What remains uncertainWhat proportion of men have a fully reversible cause has never been quantified in an unselected population.
Bottom lineA number is a finding. Ask why before asking what dose.
Strong (guideline position)
Losing weight will fix my low testosterone.
It raises testosterone substantially in most obese men and normalizes it in fewer than half.
What the evidence showsA meta-analysis of 24 studies found low-calorie dieting raised testosterone by 2.87 nmol/L (~83 ng/dL) and bariatric surgery by 8.73 nmol/L (~251 ng/dL). In a 2025 study of 69 hypogonadal men undergoing bariatric surgery, mean testosterone rose from 208 to 371 ng/dL, with 45% reaching eugonadal status.
What remains uncertainThere is no verified threshold of weight loss that predicts normalization for an individual.
Bottom lineThe highest-yield intervention available, and not a guarantee. 55% of those men still didn't normalize.
Strong
Treating sleep apnea will raise my testosterone.
Probably not — but you should treat the sleep apnea anyway.
What the evidence showsA meta-analysis of seven studies and 232 men found CPAP had no significant effect on testosterone (total T SMD −0.14, p=0.558), including when restricted to randomized trials (SMD −0.05, p=0.757). The authors concluded CPAP has no influence on testosterone in men with OSA.
What remains uncertainHow much of the OSA–testosterone association is confounded by obesity, and whether any subgroup does respond.
Bottom lineTreat OSA because it's dangerous and it causes the same symptoms. Not because it will move your testosterone.
Moderate — and this contradicts what most sites tell you
Antidepressants cause low testosterone.
Some psychiatric medications do, though the mechanism is usually prolactin rather than the antidepressant class itself.
What the evidence showsAntipsychotics with strong dopamine blockade — risperidone, haloperidol — raise prolactin, which suppresses GnRH and lowers testosterone. Depression itself also suppresses the axis, which confounds the picture.
What remains uncertainEffects of individual antidepressants on testosterone are less well characterized than the antipsychotic-prolactin pathway.
Bottom lineWorth a medication review and a prolactin level rather than an assumption.
Moderate
Opioids cause low testosterone.
Very commonly, dose-dependently, and often reversibly.
What the evidence showsReported prevalence spans 19–86%, with most studies above 50%; intrathecal morphine 86–100%; high-dose methadone around 75% in men. Risk rises above roughly 100 mg oral morphine equivalents daily. Buprenorphine and tapentadol appear to have substantially less effect.
What remains uncertainWhether testosterone recovers on tapering in chronic pain patients — the reversibility data come from heroin-dependent men.
Bottom lineIf you're on opioids and your testosterone is low, the opioids are the likeliest explanation.
Strong on the association
Testosterone treats depression.
There is a modest effect in mixed populations, and it is not a treatment for depression.
What the evidence showsA 2019 *JAMA Psychiatry* meta-analysis of 27 randomized trials and 1,890 patients found a moderate positive effect on depressive symptoms — but across heterogeneous populations rather than diagnosed major depression, and with baseline testosterone status not a significant moderator. Men who weren't deficient responded similarly to men who were.
What remains uncertainWhat actually produces the effect, given it isn't explained by correcting a deficiency.
Bottom lineDon't let a testosterone prescription delay real treatment for depression. That delay is the harm.
Limited
A high prolactin always means a pituitary tumour.
No — medications and a laboratory artifact called macroprolactin are both common explanations.
What the evidence showsMacroprolactin — biologically inert aggregated prolactin — is present in around 20% of samples with an elevated prolactin, is usually asymptomatic, and needs no treatment. It is detected by polyethylene glycol precipitation. Dopamine-blocking medications are another frequent cause.
What remains uncertainHow often macroprolactinemia leads to unnecessary treatment in practice.
Bottom lineAn elevated prolactin needs interpreting before it needs treating.
Strong
A mildly elevated prolactin rules out a large pituitary tumour.
It doesn't, and this is the more dangerous error.
What the evidence showsIn very large prolactinomas with true prolactin above 1,000 ng/mL, antibody saturation in two-site immunoassays causes a falsely low reading — often 30 to 120 ng/mL. This is the hook effect, and it can lead to a macroadenoma being misclassified as non-functioning. Serum dilution before reassay prevents it.
What remains uncertainNothing about the mechanism; it is well characterized.
Bottom lineIf the imaging shows a large tumour and the prolactin is only mildly raised, ask for a diluted sample.
Strong
Treating a prolactinoma won't fix my testosterone.
It often does, without any replacement.
What the evidence showsDopamine agonist treatment reverses hypogonadotropic hypogonadism in roughly 50 to 65% of cases, with higher baseline testosterone and smaller tumour size predicting recovery.
What remains uncertainThe timeframe to recovery, and what determines the non-responding third.
Bottom lineTreat the cause first. Testosterone can wait to see whether it's still needed.
Moderate
Thyroid problems don't affect testosterone.
They affect it in both directions, mostly through SHBG.
What the evidence showsHyperthyroidism raises SHBG and therefore total testosterone; hypothyroidism lowers SHBG and therefore total testosterone. Both are reversible with treatment of the thyroid disorder. Hypothyroidism also produces a symptom profile nearly identical to that attributed to low testosterone.
What remains uncertainWe could not verify the magnitude of these effects from primary sources.
Bottom lineA TSH is cheap and belongs in the workup.
Moderate
My fatigue must be low testosterone.
Fatigue is the least specific symptom in medicine.
What the evidence showsChronic sleep restriction, sleep apnea, depression, anemia, thyroid disease, chronic illness, medication effects and inadequate energy intake all cause fatigue, and several of them also lower testosterone. One week of five-hour nights lowered daytime testosterone by 10 to 15% in one small study.
What remains uncertainHow often fatigue in a man with borderline testosterone is genuinely hormonal.
Bottom lineIf fatigue is your only symptom, testosterone is unlikely to be your answer.
Moderate
I should start TRT now and address the underlying cause later.
This is backwards, and it forecloses options.
What the evidence showsExogenous testosterone suppresses LH and FSH — the exact measurements needed to determine where the problem originated. After months of treatment, evaluating the cause requires stopping and waiting for the axis to recover. Meanwhile the underlying condition continues untreated.
What remains uncertainNo outcomes study quantifies this harm; the reasoning is mechanistic.
Bottom lineTestosterone erases the diagnostic information you'd need later. Investigate first.
Moderate (mechanistic reasoning, not an outcomes trial)
Under-eating and overtraining can't lower testosterone that much.
They can, though the male literature is thinner than commonly implied.
What the evidence showsMale athletes and soldiers under sustained energy deficit show suppressed testosterone, including a report of castrate-level testosterone after prolonged military training. A 2024 *Endocrine Reviews* review notes conflicting results across studies and a limited male-specific literature.
What remains uncertainHow much deficit is needed, and how quickly testosterone recovers when intake increases — neither is established.
Bottom linePlausible and reversible, on weaker evidence than the fitness world assumes.
Limited
Alcohol only affects testosterone if you're an alcoholic.
Chronic heavy use clearly suppresses the axis; the threshold below that is not well defined.
What the evidence showsChronic heavy alcohol use suppresses testosterone through testicular toxicity, hepatic effects and central suppression. Acute low-dose alcohol has been reported to transiently raise testosterone — a reminder that acute and chronic effects differ.
What remains uncertainThe dose-response relationship. We could not verify a threshold and will not invent one.
Bottom lineHeavy drinking is a plausible cause. Where "heavy" begins is not well established.
Limited
If I find the cause, I should stop my TRT.
Possibly, but not unilaterally and not abruptly.
What the evidence showsIf a reversible cause is identified and corrected, endogenous production may recover — but the axis has been suppressed by treatment and takes months to restart. Stopping without a plan produces a period of symptomatic deficiency.
What remains uncertainHow to predict which men will recover adequate function after prolonged replacement.
Bottom lineWorth revisiting with your clinician. Not worth doing on your own.
Limited
Getting tested and treated quickly is better than waiting.
Getting *evaluated* quickly is better. Getting *treated* quickly is often worse.
What the evidence showsAnalysis presented at ENDO 2026 found only around 12% of men starting testosterone had a guideline-concordant diagnostic workup. The Endocrine Society advises against testing men who are acutely ill or on short-term suppressive medications at all, because the result will mislead.
What remains uncertainThe 12% figure warrants confirmation against the published abstract.
Bottom lineSpeed is a virtue in diagnosis and a liability in prescribing.
Moderate
This site is against testosterone therapy.
No. It's against prescribing it instead of making a diagnosis.
What the evidence showsTestosterone therapy has clear benefits in men with appropriately diagnosed hypogonadism from testicular, pituitary or hypothalamic disease — the Endocrine Society's July 2026 statement says exactly that. It also says testosterone appears to be overprescribed relative to guidelines.
What remains uncertainWhere precisely the line falls in the borderline cases, which is genuinely contested. See [Why Experts Don't Always Agree](/why-experts-disagree/).
Bottom lineMen who need testosterone are often under-treated. Men who don't are often treated anyway. Both are failures of diagnosis.
Strong
Where to go next
To understand what’s causing a low result: Why Is Testosterone Low?
To work through the decision: Should You Start Testosterone?
For the weight-loss route in depth: Obesity, GLP-1 Medications and Testosterone
For what actually raises testosterone without medication: Raising Testosterone Without Medication
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.